Logo

Pharsight Forms Drug Development Alliances With AstraZeneca, Quintiles

Jul 02, 1999
Premium

MOUNTAIN VIEW, Calif.--Pharsight, a clinical drug development software provider and consultancy here, has formed two partnerships: one with AstraZeneca R&D Molndal, of Sweden, and a broader one with Quintiles Transnational, a Research Triangle Park, NC-based provider of product development and commercialization services to the pharmaceutical industry.

The goal of the AstraZeneca alliance is to jointly deploy Pharsight's trial design software and methodologies for drug development to AstraZeneca's clinical development processes in a specific therapeutic area.

The Quintiles deal is part of a larger Pharsight partnership among organizations offering clinical development and scientific services.

Filed under

Informatics
Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.